Condyloma Acuminata Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The condyloma acuminata treatment market size has grown strongly in recent years. It will grow from $1.79 billion in 2024 to $1.88 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to prevalence and incidence rates, awareness and education campaigns, healthcare infrastructure, social stigma and cultural factors, regulatory environment.

The condyloma acuminata treatment market size is expected to see steady growth in the next few years. It will grow to $2.2 billion in 2029 at a compound annual growth rate (CAGR) of 4%. The growth in the forecast period can be attributed to emerging therapies, global health initiatives, changing demographics, government policies and funding, globalization and market expansion. Major trends in the forecast period include technological innovations, telemedicine and digital health, advancements in treatment technologies, rise of telemedicine and digital health solutions, global health collaboration.

The rising incidence of sexually transmitted infections (STIs) is expected to drive the growth of the condyloma acuminata treatment market in the future. STIs, also referred to as sexually transmitted diseases (STDs), are infections passed from one person to another during sexual activity. Condyloma acuminata treatment helps manage STIs by alleviating symptoms, lowering the risk of transmission, preventing complications, and promoting overall health. For example, in July 2024, the UK Health Security Agency, a government body in the UK, reported that in 2023, there were 401,800 new STI diagnoses, marking a 4.7% increase from 2022, when the total was 383,789. As a result, the growing prevalence of STIs is contributing to the expansion of the condyloma acuminata treatment market.

Leading entities within the condyloma acuminata treatment sector are actively pursuing innovation in drug development, such as podofilox gel, to enhance treatment accessibility and cost-effectiveness for patients. Podofilox gel constitutes a topical medication utilized in managing external genital and perianal warts associated with STIs. For example, in December 2023, Hyloris Pharmaceuticals SA, a Belgium-based specialty biopharmaceutical firm, disclosed FDA approval for its partner Padagis US LLC's generic version of Condylox Gel 0.5%. This topical medication is designed to address external genital and perianal warts caused by human papillomavirus (HPV), offering a therapeutic solution for specific wart types situated in genital regions such as the penis or vulva, as well as those located between the genitals and the rectum.

In August 2022, IWAKI Seiyaku Co Ltd., a contract manufacturer of pharmaceuticals based in Japan, initiated a collaboration with KinoPharma Inc. The primary objective of this collaboration is to jointly develop drug formulations targeting verruca (cutaneous warts) treatment and to ensure a stable supply of active pharmaceutical ingredients (APIs). The collaboration entails a co-development and commercialization agreement, alongside the acquisition of KinoPharma's stock through a private placement. Additionally, the collaboration involves the joint effort to develop a novel antiviral drug targeting Human Papillomavirus (HPV), aligning with the anticipated growth in the market for common warts treatment. KinoPharma Inc. specializes in the development of treatments for condyloma acuminata, making it a strategic partner for IWAKI Seiyaku Co Ltd.'s endeavors in the pharmaceutical sector.

Major companies operating in the condyloma acuminata treatment market report are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc, 3M Company, Medtronic plc, Teva Pharmaceutical Industries Ltd., IQVIA Holdings, AbbVie Inc., Astellas Pharma US Inc., Bausch Health, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Syneos Health Inc., Perrigo Company plc, Chiesi Farmaceutici S.p.A., Gedeon Richter Plc, Meda AB, Recordati Industria Chimica e Farmaceutica S.p.A., Zhejiang Hisun Pharmaceutical Co. Ltd., Mylan N.V., Ferring Pharmaceuticals AS, Indivior PLC, Parthenon Therapeutics.

North America was the largest region in the condyloma acuminata treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the condyloma acuminata treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the condyloma acuminata treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The condyloma acuminata treatment market includes revenues earned by entities by providing services such as medical consultation and evaluation, diagnostic testing, treatment planning, monitoring, and psychosocial support. The condyloma acuminata treatment market also includes sales of topical medications, home treatment kits, and immune response modulators. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Condyloma acuminata, commonly referred to as genital warts, is a sexually transmitted infection (STI) resulting from specific strains of the human papillomavirus (HPV). The primary goal of treatment is the removal of warts and the alleviation of associated symptoms. Various treatment modalities are employed to manage genital warts caused by HPV, encompassing topical agents, cryotherapy, electrocautery, and surgical excision.

The key drugs used in the treatment of condyloma acuminata include imiquimod, podophyllin and podofilox, trichloroacetic acid (TCA), sine catechins, and isotretinoin. Imiquimod, classified as an immune response modifier, is among the medications utilized for this purpose. Treatment approaches can be categorized into physical destruction, chemical destruction, and immunomodulation. These treatments are accessible through hospital pharmacies, retail pharmacies, and online pharmacies, with end-users spanning hospitals, specialty clinics, and other healthcare facilities.

The condyloma acuminata treatment market research report is one of a series of new reports that provides condyloma acuminata treatment market statistics, including condyloma acuminata treatment industry global market size, regional shares, competitors with a condyloma acuminata treatment market share, detailed condyloma acuminata treatment market segments, market trends and opportunities, and any further data you may need to thrive in the condyloma acuminata treatment industry. This condyloma acuminata treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.